Trials / No Longer Available
No Longer AvailableNCT03433807
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Santhera Pharmaceuticals · Industry
- Sex
- All
- Age
- 8 Years
- Healthy volunteers
- —
Summary
The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idebenone | 900 mg idebenone/day (2 tablets to be taken 3 times a day with meals) |
Timeline
- First posted
- 2018-02-15
- Last updated
- 2023-04-21
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03433807. Inclusion in this directory is not an endorsement.